[go: up one dir, main page]

MX2016015211A - Formulaciones topicas y usos de las mismas. - Google Patents

Formulaciones topicas y usos de las mismas.

Info

Publication number
MX2016015211A
MX2016015211A MX2016015211A MX2016015211A MX2016015211A MX 2016015211 A MX2016015211 A MX 2016015211A MX 2016015211 A MX2016015211 A MX 2016015211A MX 2016015211 A MX2016015211 A MX 2016015211A MX 2016015211 A MX2016015211 A MX 2016015211A
Authority
MX
Mexico
Prior art keywords
formulations
topical formulations
conditions
methods
diseases
Prior art date
Application number
MX2016015211A
Other languages
English (en)
Inventor
L Weiss Sidney
Original Assignee
Ocular Tech Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54554700&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016015211(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ocular Tech Sarl filed Critical Ocular Tech Sarl
Publication of MX2016015211A publication Critical patent/MX2016015211A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporcionan en la presente formulaciones incluidas para administración tópica, tal como formulaciones oftálmicas, y métodos de uso de tales formulaciones. En algunos aspectos y modalidades, las formulaciones pueden incluir un lípido polioxilo o ácido graso, y/o un alcohol polialcoxilado y pueden incluir nanomicelas. También se incluyen métodos para tratar o prevenir enfermedades o afecciones, tales como enfermedades o afecciones oculares.
MX2016015211A 2014-05-23 2015-05-20 Formulaciones topicas y usos de las mismas. MX2016015211A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462002682P 2014-05-23 2014-05-23
PCT/US2015/031788 WO2015179527A1 (en) 2014-05-23 2015-05-20 Topical formulations and uses thereof

Publications (1)

Publication Number Publication Date
MX2016015211A true MX2016015211A (es) 2017-06-20

Family

ID=54554700

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016015211A MX2016015211A (es) 2014-05-23 2015-05-20 Formulaciones topicas y usos de las mismas.

Country Status (13)

Country Link
US (2) US20170065611A1 (es)
EP (1) EP3145549A4 (es)
JP (1) JP2017519813A (es)
CN (1) CN106794254A (es)
AU (1) AU2015264181A1 (es)
BR (1) BR112016027379A2 (es)
CA (1) CA2949954A1 (es)
EA (1) EA201692402A1 (es)
HK (1) HK1231376A1 (es)
IL (1) IL248934A0 (es)
MX (1) MX2016015211A (es)
SG (1) SG11201609742VA (es)
WO (1) WO2015179527A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4218729A1 (en) 2012-08-24 2023-08-02 Sun Pharmaceutical Industries Limited Topical formulations and uses thereof
ES2584534B1 (es) * 2015-03-27 2017-03-13 Retinset, S.L. Formulación tópica oftálmica de bosentan
EP4364810A3 (en) 2015-11-10 2024-07-24 Sun Pharmaceutical Industries Limited Topical formulations and uses thereof
NZ785158A (en) 2016-02-29 2025-03-28 Sun Pharmaceutical Ind Ltd Topical cyclosporine-containing formulations and uses thereof
WO2017152129A2 (en) * 2016-03-03 2017-09-08 Ocular Technologies Sarl Treatment of glaucoma and/or retinal diseases and formulations useful therefore
US20190209465A1 (en) * 2016-07-01 2019-07-11 Pharmathen S.A. Process for preparing pharmaceutical ophthalmic compositions of brinzolamide
EP3843704B1 (en) * 2018-08-28 2023-12-20 Cloudbreak Therapeutics, LLC Emulsion formulations of multikinase inhibitors
JP2024516829A (ja) * 2021-04-30 2024-04-17 パフューズ セラピューティクス， インコーポレイテッド エンドセリンレセプターアンタゴニストを使用する眼疾患の処置
WO2024236599A1 (en) * 2023-05-16 2024-11-21 Micro Labs Limited Ophthalmic solution of brinzolamide

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7678836B2 (en) * 1999-11-04 2010-03-16 Fxs Ventures, Llc Method for rendering a contact lens wettable
US20040213782A1 (en) * 2003-02-03 2004-10-28 Pharmacia Corporation Compositions of an aquaporin modulating agent and an aqueous humor modulating agent for the treatment of elevated intraocular pressure
CA2615990A1 (en) * 2005-07-18 2007-01-25 Minu, L.L.C. Enhanced ocular neuroprotection/neurostimulation
US9456980B2 (en) * 2007-08-29 2016-10-04 Wakamoto Pharmaceutical Co., Ltd. Latanoprost-containing aqueous pharmaceutical composition
MX2007011165A (es) * 2007-09-12 2009-03-11 Arturo Jimenez Bayardo Composición farmacéutica estable de timolol, dorzolamida y brimonidina.
TWI544927B (zh) * 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
JP2010037327A (ja) * 2008-07-07 2010-02-18 Wakamoto Pharmaceut Co Ltd ブリンゾラミド水性組成物
US9095506B2 (en) * 2008-11-17 2015-08-04 Allergan, Inc. Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
RU2012115103A (ru) * 2009-09-17 2013-10-27 Сэндзю Фармасьютикал Ко., Лтд. Водные глазные капли, содержащие латанопрост, и способ ингибирования адсорбции латанопроста полимером
US20130065888A1 (en) * 2011-08-15 2013-03-14 Biserka Cetina-Cizmek Ophthalmic formulations and processes for their preparation
KR20150028241A (ko) * 2012-05-11 2015-03-13 시플라 리미티드 약학적 조성물
EP4218729A1 (en) * 2012-08-24 2023-08-02 Sun Pharmaceutical Industries Limited Topical formulations and uses thereof

Also Published As

Publication number Publication date
CN106794254A (zh) 2017-05-31
US20180092927A1 (en) 2018-04-05
US20170065611A1 (en) 2017-03-09
EP3145549A4 (en) 2018-02-14
WO2015179527A1 (en) 2015-11-26
AU2015264181A1 (en) 2016-12-01
EP3145549A1 (en) 2017-03-29
HK1231376A1 (zh) 2017-12-22
JP2017519813A (ja) 2017-07-20
EA201692402A1 (ru) 2017-03-31
IL248934A0 (en) 2017-01-31
BR112016027379A2 (pt) 2018-06-26
SG11201609742VA (en) 2016-12-29
CA2949954A1 (en) 2015-11-26

Similar Documents

Publication Publication Date Title
MX2015002239A (es) Formulacion oftalmica de lipido polioxilo o de acido graso polioxilo y tratamiento de padecimientos oculares.
MX2016015211A (es) Formulaciones topicas y usos de las mismas.
NZ755442A (en) Topical cyclosporine-containing formulations and uses thereof
MX2023003124A (es) Composiciones farmaceuticas oftalmicas y usos que se relacionan a las mismas.
BR112015021888A8 (pt) inibidores de dna-pk, seus usos e composição farmacêutica
PH12018501072A1 (en) Modified release orally administered amino acid formulations
CL2013002134A1 (es) Composicion farmaceutica oftalmica de administracion topica que comprende un androgeno; y metodo para tratar una afeccion ocular resultante de una deficiencia de androgeno.
MX2016011841A (es) Composiciones topicas de corticosteroides.
WO2013171764A3 (en) Ophthalmic formulations
MX2020003534A (es) Composiciones oftalmicas que comprenden latanoprost para usarse en el tratamiento de las enfermedades oculares.
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
PH12017500602A1 (en) Methods for treating ocular conditions
EP4420722A3 (en) Modified fibroblast growth factors for the treatment of ocular disorders
PH12015502556A1 (en) Modified release formulation
MA56220A (fr) Formulations oculaires permettant l'administration de médicament et la protection du segment antérieur de l'oeil
WO2016030899A8 (en) Methods of treating amyotrophic lateral scleroses
TR201905218T4 (tr) Nörodejenerati̇f hastaliklarin tedavi̇si̇ i̇çi̇n yararli vi̇tanoli̇dler.
EP3167893A4 (en) Pharmaceutical composition containing spirulina maxima extract as active ingredient for preventing and treating retinal diseases
EP4364810A3 (en) Topical formulations and uses thereof
WO2017152129A3 (en) Treatment of glaucoma and/or retinal diseases and formulations useful therefore
MX2018005226A (es) Formulaciones de anticuerpo anti-factor d.
WO2017129577A8 (en) Ophthalmic gabapentin for the treatment of corneal ulcers
PH12015501538A1 (en) Topical ocular analgesic agents
MX2016011706A (es) Formulaciones de progesterona.
HK1219654A1 (zh) 用於治療眼科疾病和病症的方法